Abstract
PURPOSE: Ambrisentan is a propanoic acid-class, ETA-selective endothelin receptor antagonist that has been shown to improve efficacy in two Phase 3 placebo-controlled studies (ARIES-1 and ARIES-2) of patients with pulmonary arterial hypertension (PAH). The efficacy and safety of ambrisentan was assessed in these studies for patients with idiopathic PAH (IPAH) or PAH associated with connective tissue diseases (PAH-CTD).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
